CYDY News and Press, CytoDyn Inc From 08/28/20

CytoDyn ( OTCQB:CYDY ) will host a conference call on Wednesday, September 2, at 4:00 pm ET to update investors on all of its regulatory and clinical initiatives including its activities related to leronlimab in COVID-19. More news on: CytoDyn Inc., Healthcare stocks news, Read mor...

VANCOUVER, Washington, Aug. 28, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

Months into the global pandemic, the world is up to 23.9 million cases, with 820,286 unfortunate deaths. In the U.S., we're up to 5.78 million infections. In Brazil, nearly 3.7 million. In India, 3.23 million. In Russia, 968,297, and in South Africa, 613,017. While no company has a magic cure...

According to a senior administration official, CytoDyn ( OTCQB:CYDY -4.7% ) is not being considered for inclusion in Operation Warp Speed, dashing enthusiasm of hopeful longs after IncellDx CEO Bruce Patterson, a former advisor to CytoDyn, told TV host Dr. Drew Pinksy that he thought the...

CytoDyn (CYDY) shareholders experienced a big letdown following its exhilarating, albeit brief, sprint to $10.00 back in late July. Now, one short month later [pun intended], the floor seems to have fallen away. CytoDyn has breached the $3.00 level on several occasions recently. On Frida...

CytoDyn ( OTCQB:CYDY ) has reached the requisite number of enrolled patients in its Phase 3 trial of leronlimab in COVID-19 patients with severe-to-critical symptoms to perform an interim analysis following the 28-day phase of the trial, with results anticipated by mid-October....

Interim analysis to commence after 28 days; results anticipated by mid-October VANCOUVER, Washington, Aug. 25, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140),...

Patient enrollment to commence immediately  VANCOUVER, Washington, Aug. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the p...

VANCOUVER, Washington, Aug. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA G1 Therapeutics Inc. ( GTHX ) reported that the FDA has accepted its New Drug Application of its lead drug candidate, Trilaciclib. The FDA has given Priority Review status to the NDA, and the PDUFA action date has ...